Intellia Therapeutics
NTLA
285 hedge funds and large institutions have $2.53B invested in Intellia Therapeutics in 2023 Q3 according to their latest regulatory filings, with 34 funds opening new positions, 120 increasing their positions, 66 reducing their positions, and 36 closing their positions.
82% more repeat investments, than reductions
Existing positions increased: 120 | Existing positions reduced: 66
1.75% more ownership
Funds ownership: 88.8% → 90.55% (+1.8%)
4% more call options, than puts
Call options by funds: $13.4M | Put options by funds: $12.8M
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
6% less first-time investments, than exits
New positions opened: 34 | Existing positions closed: 36
2% less funds holding
Funds holding: 290 → 285 (-5)
21% less capital invested
Capital invested by funds: $3.19B → $2.53B (-$656M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$45.2M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$16.4M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
+$15.4M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$14.2M |
| 5 |
Morgan Stanley
New York
|
+$9.38M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Charles Schwab
San Francisco,
California
|
-$10.5M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$9.64M |
| 3 |
IHAM
Integral Health Asset Management
New York
|
-$8.4M |
| 4 |
Goldman Sachs
New York
|
-$8.05M |
| 5 |
Nomura Holdings
Tokyo,
Japan
|
-$7.55M |
NTLA Hedge Fund Activity: Q3 2023 in Review
285 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Intellia Therapeutics (NTLA) for Q3 2023, worth a combined $2.53B — down 21% from $3.19B a quarter earlier.
Sellers outnumbered buyers: 36 funds closed out of NTLA and 34 opened new positions — a net loss of 2 holders — while 66 trimmed existing stakes and 120 added.
The largest buyer was Deep Track Capital, adding an estimated $45.2M. The largest seller was Charles Schwab, cutting an estimated $10.5M.
- 285 institutional investors held Intellia Therapeutics (NTLA) as of Q3 2023, down from 290 in Q2 2023.
- Funds reported $2.53B of Intellia Therapeutics stock for Q3 2023, down 21% quarter-over-quarter.
- 34 funds opened new Intellia Therapeutics positions in Q3 2023 and 36 closed out, a net change of -2 holders.
- The largest Intellia Therapeutics buyer in Q3 2023 was Deep Track Capital, an estimated $45.2M added.
- The largest Intellia Therapeutics seller in Q3 2023 was Charles Schwab, an estimated $10.5M sold.
Based on aggregated 13F filings for Q3 2023.